Adimab Hooks GSK, Expands Biogen Alliance
Despite the proliferation of biotech initial public offerings (IPO) this year – including two that priced yesterday (see the related story in this issue) – Adimab LLC is distinctly disinterested in the public markets. And the Lebanon, N.H., firm can well afford to remain private. Early Friday morning, the company disclosed two more in a string of lucrative deals that catapulted it to profitability just three years after its 2007 launch.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST